Screener
Maze Therapeutics MAZE EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Maze Therapeutics’s reported figures.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
FAQ
- What is Maze Therapeutics's EBITDA?
- Maze Therapeutics (MAZE) reported EBITDA of -$47.64M in Q2 2026.
- How has Maze Therapeutics's EBITDA changed year-over-year?
- Maze Therapeutics's EBITDA decreased by 33.0% year-over-year, from -$35.83M to -$47.64M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Maze Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude